We just covered the
10 Best Non-AI Stocks to Buy According to Billionaire Stanley Druckenmiller. NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) ranks #5 (see 5 Best Non-AI Stocks to Buy According to Billionaire Stanley Druckenmiller).
Druckenmiller’s Stake: $98,275,000
Druckenmiller likes asymmetric bets where he can risk a small position for potentially large upside. NAMS falls in this category. It’s a Netherlands-based biotech developing obicetrapib, an oral drug designed to lower bad cholesterol. The product is targeted towards people who are not able to reach target levels even after taking standard treatments like statins.
A lot of patients with cardiovascular disease or high cholesterol are still not able to reach LDL targets even with existing therapies, which creates a large unmet medical need for an easy-to-take oral option.
If approved, it could become a widely used add-on therapy with global demand; if it fails in key outcome trials or regulatory review, the downside is significant because there is little diversification in the pipeline.
TimesSquare Capital U.S. Small Cap Growth Strategy stated the following regarding NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) in its fourth quarter 2025 investor letter:
“Our preferences among Health Care stocks are those companies providing novel therapies for unmet needs that command premium pricing, or specialized service providers. Shares in the biopharma developer of cholesterol inhibitors for cardiovascular diseases, NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS), rose by 23%. Indications were strongly positive for the upcoming trial results for its CETP inhibitor to reduce LDL levels (Click Here to Read the Letter in Detail).”
While we acknowledge the potential of NAMS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.
Disclosure: None. Follow Insider Monkey on Google News.